Life Science News

Naturally Splendid Enterprises Ltd. announces its unaudited financial results for the nine months ended September 30, 2021. All amounts are in Canadian dollars and are prepared in accordance with International Financial Reporting Standards Naturally Splendid CEO Mr. Craig Goodwin reports, "The Company continues to execute on our strategic plan developing, manufacturing and distributing plant-based, meat alternative ...

Naturally Splendid Enterprises Ltd. ("Naturally Splendid", "NSE" or "the Company") (FSE:50N)(TSXV:NSP)(OTC PINK:NSPDF) announces its unaudited financial results for the nine months ended September 30, 2021. All amounts are in Canadian dollars and are prepared in accordance with International Financial Reporting Standards

Naturally Splendid CEO Mr. Craig Goodwin reports, "The Company continues to execute on our strategic plan developing, manufacturing and distributing plant-based, meat alternative entrees. Having identified plant-based entrees as our priority, work has already begun retrofitting our existing food manufacturing facility located in British Columbia. This includes installation of a state-of-the-art packaging line which has already been initiated. This line is expected to be operational in the next 30 - 45 days. Once fully operational, this new packaging line creates significant opportunities in the retail market by providing a wide range of packaging formats that can then be placed in both chiller and freezer sections of grocery stores. The versatility of this packaging line creates opportunities for sales in multiple formats for different placement in stores across a wide range of potential clients, ultimately resulting in increased sales.

Goodwin adds, "The Company has announced a private placement of which funding will be directed towards the purchase and installation of a high output manufacturing line that will be capable of initially producing a ton an hour output of a wide variety of plant-based entrees. This capacity is expected to increase up to 1,000 kgs to 1,500 kgs per hour within the same manufacturing footprint as efficiencies are achieved.

This line has been selected for the ability to manufacture our plant-based foods to the exacting standards of our Australian partners, Flexitarian Foods. Selection and installation of this manufacturing line is being assisted directly by key members of the Flexitarian Foods team who have travelled from Australia and are currently in the process of their onsite evaluations in order to optimize efficiencies of manufacturing line. Key members of Flexitarian Foods will then also be instrumental in the training of the Naturally Splendid production team to assure our clients that they will be receiving the same high-quality products that are currently produced in Australia".

NATERA Plant Based Food entrees were listed at the British Columbia Institute of Technology (BCIT), the first of what we anticipate to be multiple listings at post-secondary institutions across Canada".

Working with our existing distribution network including Sysco, Gordon Food Service (GFS) and Canex Foods, the Company has representation in major centres across Canada and expects to increase our food service clientele through this network as well as from our own sales initiatives".

The Company has recently announced a direct to consumer, distribution arrangement with Sealand Quality Foods and look to add additional direct to consumer partners to service specific regions and demographics. As consumer shopping habits have changed, driven in large part by the continued challenges posed by the on-going pandemic, additional direct to consumer distribution arrangements will be added to in order to meet the expectations of this growing segment who are adapting to new ways to shop for their groceries.

Naturally Splendid CFO, Mr. Bryan Carson states, "As reported in previous news releases, establishing the new manufacturing and packaging lines in our existing facility requires significantly less capital than would be required to build out an entirely new manufacturing facility. It must also be noted that the ‘learning curve' that is associated with the implementation of a new production line is minimized with the assistance of the Flexitarian Foods team. Manufacturing NATERA Plant Based Foods in Canada rather than importing from Australia will have many advantages including access to ingredients and supplies more readily available in Canada, improved inventory controls and significantly reduced logistic challenges, thus resulting not only in increased margins, but will also bring forth additional opportunities to the Company expanding our current client list, ultimately resulting in improved top and bottom line sales."

Carson further states, "The Company continues to evaluate on-going projects including the Health Canada approved Phase 2 clinical trial for a potential Covid treatment as well as our our bar manufacturing business. In regard to the Health Canada approved clinical trial, we have all been optimistic that the pandemic was on the decline which effected our decisions in how to proceed to trial. However, with the most recent developments surrounding the announcements by the World Health Organization as it relates to the latest mutation of the Covid virus, renewed efforts will be forthcoming looking to partner with experienced pharma companies to get Cavaltinib to trial.

Manufacturing of bars and bites had been a priority up until the pandemic. The bars and bite business has been negatively affected due in part to ingredient supply chain challenges. Challenges related to supply chain logistics needed to be reviewed which required an in-depth evaluation of this division. The Company is developing strategic plans around this opportunity that will allow the Company to begin the recovery of this division. The Company will provide further updates to both the Health Canada trial and the bars and bites manufacturing in the near future."

Financial Reporting Standards.

Naturally Splendid recorded a net loss and comprehensive loss of $2,486,566 for the nine months ended September 30, 2021, compared to a net loss of $3,340,159 during the nine months ended September 30, 2020. The decrease in net loss and comprehensive loss was attributed to the decrease in selling and distribution expenses. Gross profit margins increased by 2.4% of sales in the nine months ended September 30, 2021, compared to the nine months ended September 30, 2020, this is predominately due to the increased profit margins in the new plant-based sales. The Company's sales decreased by approximately $729,000 from the comparative period. During the nine-month period ended September 30, 2021, selling and distribution expense decreased by approximately $512,600 largely due to decreased in production (facility costs, quality assurance and lab testing) and production wages which were offset by the government wage subsidy received during the quarter. Administrative expenses decreased by approximately $431,000 predominantly from office, rent and salaries and corporate promotions. The decrease was attributed to a reduction in investor relations activity due to the pandemic and the reduction of corporate salaries from the government wage subsidy.

Naturally Splendid recorded sales of $619,653 during the nine months ended September 30, 2021, compared to $1,348,831 in for nine months ended September 30, 2020. The Company's sales decreased by approximately $729,000 from the comparative period. The Company had decreased sales in its private label bars and bites business by approximately $694,000 and other branded products decreased by approximately $6,000. Branded hemp products decreased by approximately $83,000 and its Natera Sport products decreased by approximately $130,000. The Company's new Plant-based products had sales of approximately $79,000 during the quarter ended September 30, 2021. During the nine months period ended September 30, 2021, the new Plant-based product sales were approximately $184,000.

Cost of Sales during the nine months ended September 30, 2021, and 2020 were $539,187 and $1,205,901 respectively. The Company gross margin percentage is 13% of sales, during the nine months ended September 30, 2021

The Company continued its sales mix with exports of bulk seed and launching its new plant-based products. The bulk hemp seeds sold at a lower gross margin percentage then compared to the plant-based products and private label sales. The Company is now focused on its higher margin products and new commercial opportunities. Gross profits for the nine months ended September 30, 2021, was $80,466 (13% of sales) compared to $142,930 (11% of sales) for nine months ended September 30, 2020. The best market opportunities for NSE have been both domestic and new international destinations along with Prosnack Natural Foods Inc. private label products.

For the Three Months Ended September 30, 2021 For the Three Months Ended September 30, 2020 For the Nine Months Ended September 30, 2021 For the Nine Months Ended September 30, 2020
$ $ $ $
Statements of Loss Data
Revenue
149,614 323,195 619,653 1,348,831
Cost of sales
(144,375) (292,827) (539,187) (1,205,901)
Gross Profit
5,239 30,368 80,466 142,930
Selling and distribution expenses
(160,991) (246,776) (589,659) (1,102,254)
Administrative expenses
(576,803) (714,191) (1,980,488) (2,411,898)
Other income(loss) and taxes
(735,578) (911,215) (2,486,566) (3,340,159)
Net income (loss)
(735,578) (911,215) (2,486,566) (3,340,159)
Basic and Diluted Earnings (Loss)
Per Share
(0.00) (0.00) (0.01) (0.02)

About Naturally Splendid Enterprises Ltd.

Founded in 2010, NSE operates a food manufacturing facility just outside Vancouver, BC in Canada. The Company has established numerous healthy, functional foods under recognized brands such as Natera Sport™, Natera Hemp Foods, CHII, Elevate Me™ and Woods Wild Bar™, and most recently Natera Plant Based Foods, a line of delicious plant-based meat alternatives for the rapidly growing plant-based market segment. The Company has a myriad of new products and line extensions under development that are approaching launch. NSE, through its joint venture Plasm Pharmaceutical, has been approved for conducting a phase 2 clinical trial approved by Health Canada for treatment of COVID-19. NSE has also developed proprietary technologies for the extraction of high-demand, healthy omega 3 and 6 oils from hemp.

NSE contract manufacturers for healthy, functional food products and ingredients focusing on plant-based ingredients. The Company provides contract manufacturing services for many healthy food companies, private labeling a wide variety of nutritional food products destined for global healthy food markets.

For more information e-mail info@naturallysplendid.com or call Investor Relations at 604-465-0548 (ext. 105)

On Behalf of the Board of Directors
Mr. J. Craig Goodwin CEO, Director

Contact Information

Naturally Splendid Enterprises Ltd.
(NSP - TSX Venture; NSPDF - OTCQB; 50N - Frankfurt)
#108-19100 Airport Way
Pitt Meadows, BC, V3Y 0E2
Office: (604) 465-0548
Fax: (604) 465-1128
E-mail: info@naturallysplendid.com
Website: www.naturallysplendid.com

Forward-Looking Statements

Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management's current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. Naturally Splendid cautions that all forward looking statements are inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond Naturally Splendid's control including, Naturally Splendid's ability to compete with large food and beverage companies; sales of any potential products developed will be profitable; sales of shelled hemp seed will continue at existing rates or increase; the ability to complete the sales of all bulk hemp seed purchase orders; and the risk that any of the potential applications may not receive all required regulatory or legal approval. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Except as required under applicable securities legislation, Naturally Splendid undertakes no obligation to publicly update or revise forward-looking information.

NEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

SOURCE: Naturally Splendid Enterprises Ltd.



View source version on accesswire.com:
https://www.accesswire.com/675096/Naturally-Splendid-Reports-Third-Quarter-Results-for-2021

News Provided by ACCESSWIRE via QuoteMedia

Naturally Splendid

Naturally Splendid

Overview

Keep reading... Show less

U.S. FDA Approves RINVOQ® to Treat Adults and Children 12 Years and Older with Refractory, Moderate to Severe Atopic Dermatitis

ABBVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration (FDA) has approved RINVOQ ® (upadacitinib) for the treatment of moderate to severe atopic dermatitis in adults and children 12 years of age and older whose disease did not respond to previous treatment and is not well controlled with other pills or injections, including biologic medicines, or when use of other pills or injections is not recommended. 1 RINVOQ 15 mg once daily can be initiated in adults and children 12 years of age and older weighing at least 40 kg. 1 In these children and adults less than 65 years of age who do not achieve an adequate response, the dose may be increased to 30 mg once daily. 1

"Early in my career as an allergist, I saw how relentless the itch and rash could be for my patients with moderate to severe atopic dermatitis yet had limited options to offer those whose disease could not be adequately controlled with systemic therapy," said Thomas Hudson , M.D., senior vice president, research and development, chief scientific officer, AbbVie. "This additional approval for RINVOQ provides a once-daily oral option that can significantly improve the debilitating itch and skin symptoms of atopic dermatitis. It's also a proud moment for AbbVie as we continue our efforts to improve care in this disease state and other chronic, immune-mediated conditions."

Keep reading... Show less
Naturally Splendid Closes Second Tranche of $1,120,456 for a Total Raise of $3,270,971

Naturally Splendid Closes Second Tranche of $1,120,456 for a Total Raise of $3,270,971

Naturally Splendid Enterprises Ltd. ("Naturally Splendid" or "NSE" or the "Company" ) (FRANKFURT:50N)(TSXV:NSP)(OTC PINK:NSPDF) announces that it has closed the second tranche of its previously announced non-brokered private placement financing (the "Financing") (see news release dated November 23, 2021 and December 23, 2021) by issuing 37,348,532 Units (each a "Unit") at a price of $0.03 per Unit for gross proceeds of $1,120,455.96 (the "Second Tranche"). In total, the Company has issued 109,032,378 Units for gross proceeds of $3,270,971.34 under the entire private placement financing. The Financing has been oversubscribed by $270,971.34

Each Unit in the Second Tranche consists of one common share of Naturally Splendid and one common share purchase warrant (each a "Warrant"), with each Warrant entitling the holder to purchase one additional common share for a period of two years from the date of the issue at an exercise price of $0.05 per share.

Keep reading... Show less

TEZSPIRE NOW AVAILABLE IN THE UNITED STATES FOR THE TREATMENT OF SEVERE ASTHMA

- Amgen (NASDAQ:AMGN) and AstraZeneca today announced TEZSPIRE™ (tezepelumab-ekko) is now available for shipment to wholesalers in the U.S. TEZSPIRE was approved by the U.S. Food and Drug Administration (FDA) on Dec. 17, 2021 for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma. 1

"Severe asthma has historically been a complex disease for patients to manage and for physicians to treat," said Murdo Gordon , executive vice president of Global Commercial Operations at Amgen. "About 60 percent of people have multiple drivers of disease and may not respond well to existing treatments. TEZSPIRE was approved for a broad population of people living with severe asthma, and we look forward to getting this important medicine into the hands of millions of patients who have had an unmet medical need."

Keep reading... Show less
Komo Plant Based Foods to Launch in Whole Foods Market Retail Locations in Western Canada

Komo Plant Based Foods to Launch in Whole Foods Market Retail Locations in Western Canada

Komo Plant Based Foods Inc. (CSE:YUM)(OTCQB:KOMOF)(FRA:9HB) ("Komo"), a premium plant-based food company, is pleased to announce all 7 Whole Foods Market retail locations in Western Canada will begin carrying Komo Plant Based Comfort Foods. Komo products are planogrammed to be on the shelves in all 7 stores in early 2022. Whole Foods has expanded to 6 stores within key neighbourhoods in the greater Vancouver area and most recently opened a flagship store in the capital city of Victoria on southern Vancouver Island

Whole Foods Market, Inc. is an American multinational supermarketchain headquartered in Austin, Texas, which sells organic foods and products free from hydrogenated fats and artificial colors, flavors, and preservatives. Whole Foods seeks out the finest natural and organic foods available, maintains the strictest quality standards in the industry, and has an unshakeable commitment to sustainable agriculture. Whole Foods has more than 500 retail and non-retail locations in the US, Canada and the United Kingdom. It has 14 retail locations in Canada, of which 7 are in British Columbia, and 7 are in Ontario. In 2017, Amazon purchased Whole Foods Market for USD$13.7 Billion.

Keep reading... Show less

Top Canadian Biotech Stocks

Click here to read the previous top Canadian biotech stocks article.

Although it’s not as large as the US biotech industry, the Canadian biotech market is still making a name for itself on the global investment stage in terms of size and opportunities.

In recent years, the biotech sector worldwide has become a “real industry” that has brought “spectacular” returns for mid-cap companies, according to Jessica Chutter, managing director and chairman of biotechnology investment banking with Morgan Stanley (NYSE:MS).

Much of the growth in biotech is attributable to technology advancements in drug research and development, said Chutter, who was speaking at a virtual event hosted by the Globe and Mail.

Keep reading... Show less
Solarvest To Sell on China's E-Commerce Application Redbook

Solarvest To Sell on China's E-Commerce Application Redbook

(TheNewswire)

Solarvest BioEnergy Inc.

Solarvest ( TSXV:SVS ) is pleased to announce that the Eversea TM "branded" account has been launched on the Chinese e-commerce platform application Redbook

Keep reading... Show less

Latest Press Releases

Related News

×